A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial
暂无分享,去创建一个
D. Lambrechts | H. Denys | F. Selle | E. Van Nieuwenhuysen | A. Van Rompuy | F. Kridelka | Tine Ottenbourgs | T. van Gorp | T. Baert | Inge Baas
[1] Su-Chun Cheng,et al. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Hooft,et al. Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review , 2022, Cancers.
[3] N. Bradshaw,et al. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. , 2021, Gynecologic oncology.
[4] J. Copland,et al. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers , 2020, ESMO Open.
[5] F. Marmé,et al. LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial , 2020, Annals of Oncology.
[6] A. deFazio,et al. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. , 2019, Gynecologic oncology.
[7] M. Goetz,et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Reuss,et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. , 2016, Gynecologic oncology.
[9] G. Kenter,et al. Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary , 2015, Acta obstetricia et gynecologica Scandinavica.
[10] M. Coleman,et al. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] M. Buist,et al. Hormone therapy in ovarian granulosa cell tumors: a systematic review. , 2014, Gynecologic oncology.
[12] D. Bodurka,et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. , 2012, Gynecologic oncology.
[13] A. Sood,et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. , 2009, Gynecologic oncology.
[14] J Jack Lee,et al. A predictive probability design for phase II cancer clinical trials , 2008, Clinical trials.
[15] Liège, Belgium , 2019, The Statesman’s Yearbook Companion.